Background {#Sec1}
==========

Sepsis-associated acute kidney injury (S-AKI) is a major public health condition that is associated with a significant disease burden. S-AKI is a syndrome of acute functional impairment and organ damage that could be associated with long-term adverse outcomes. Sepsis is the most common cause of acute kidney injury (AKI) in critically ill patients, and is observed in 40--50% of patients with AKI \[[@CR1]--[@CR4]\]. Of particular importance is the fact that S-AKI is closely associated with poor clinical outcomes. For instance, the mortality rate of sepsis patients with AKI complications is significantly higher than that of non-AKI patients \[[@CR5]\]. Among critically ill patients with AKI, S-AKI is correlated with a higher risk of in-hospital death and longer durations in hospital than AKI caused by any other reasons \[[@CR3]\]. Despite significant advances in medicine and surgical treatment, the morbidity associated with this condition remains rather high. Mounting evidence suggests that the incidence of AKI incidence is steadily increasing. A previous 10-year cohort study, including more than 90,000 patients from more than 20 ICUs, indicated that the incidence of AKI incidence has increased by 2.8% per year \[[@CR1]\]. Moreover, along with the global trend for aging, the majority of patients with sepsis are elderly; furthermore, the number of patients with sepsis-associated AKI is likely to continue to increase \[[@CR6], [@CR7]\]. Sepsis-associated AKI is associated with a high burden of morbidity and mortality in both children and adults with critical illness. Unfortunately, the pathogenesis of S-AKI is still not completely understood. There are also difficulties in the early diagnosis and treatment of S-AKI that need to be solved. Therefore, it is vital that we develop tools to identify the risk factors of S-AKI early so that we can attempt to prevent this disease. Although a number of studies have explored the risk factors associated with the development of AKI in patients with sepsis, clinical opinions remain inconclusive due to regional differences and inconsistencies in the diagnostic criteria relating to sepsis and AKI. In this study, we aimed to systematically review previous observational studies (cohort/case-control studies) and to perform meta-analyses with the eligible evidence to investigate the association between sepsis and AKI.

Methods {#Sec2}
=======

Inclusion criteria {#Sec3}
------------------

Studies that met the following criteria were included for data extraction: (1) Patients needed to be older than 16 years with a hospitalization stay of greater than 24 h; (2) Studies needed to contain information presented in a 2 × 2 contingency table; (3) Sepsis and septic shock needed to be diagnosed using internationally-recognized standards, such as sepsis 1.0 \[[@CR8]\], sepsis 2.0 \[[@CR9]\], or sepsis 3.0 \[[@CR10]\]; (4) Acute kidney injury needed to be diagnosed using internationally-recognized standards, such as KDIGO, AKIN, and RIFLE; (5) Cohort or case-control studies needed the patients to be grouped into sepsis with AKI and sepsis without AKI.

Data sources and search strategy {#Sec4}
--------------------------------

A systematic review and meta-analysis of scientific peer-reviewed literature was performed by following the recommendations from the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guideline (see Additional file [1](#MOESM1){ref-type="media"}) \[[@CR11]\].

The systematic literature search was performed in Medline, Embase, Cochrane Library, PubMed, and Web of Science, databases from inception to June 2019 with no restrictions. The search aimed to retrieve studies that assessed the risk of AKI development in patients with sepsis. The following search terms were used: (septic OR sepsis OR severe sepsis OR Septicemia OR septic shock OR sepsis-associated OR sepsis-associated) AND (Acute Kidney Injury OR Acute Renal Injury OR Acute Renal Insufficiency OR AKI OR acute renal failure OR ARF). The reference lists of the included articles were also manually retrieved. We did not include gray literature (literature that has not published) or conference abstracts.

Data extraction {#Sec5}
---------------

Two independent reviewers participated in the entire process of literature retrieval. First-round screening was performed based on the title and abstract so that we could exclude studies on irrelevant topics. Next, the included articles were screened based on full text; non-eligible articles that did not meet the inclusion criteria were excluded. Data extraction was performed using a standardized data collection form, including: (1) study characteristics: publication year, study design, country of origin, diagnostic criteria for sepsis and acute kidney injury, type of sepsis, period of data report; (2) the number of 2 × 2 contingency tables and unadjusted crude odds ratios with regards to demographic data (gender) and the independent variables/predictors under investigation (comorbidities, source of infection, medication, invasive treatment, types of sepsis, and blood culture); and (3) outcome: the primary endpoint was S-AKI; the secondary outcome was the prevalence of influential factors and mortality in patients with S-AKI.

Quality assessment {#Sec6}
------------------

Study selection, data extraction, and quality assessments were independently performed by two authors. Any disagreements were resolved through discussions until a consensus was reached. If disagreements persisted, another reviewer would be invited to the discussion to achieve a final consensus. Quality assessment of the observational studies that were included in the meta-analysis was performed using the Newcastle-Ottawa scale (available at <http://www.ohri.ca/programs/clinical_epidemiology/oxf> ord.asp).

Statistical analysis {#Sec7}
--------------------

The core characteristics of the study and patients were sorted and summarized. The frequency distribution was expressed as a percentage. For meta-analysis, we only used non-adjusted crude odds ratios (OR) from no less than 3 studies to standardize the results; this was due to the significant variability of multivariable models across different studies. Stata/SE version 11 was used for all statistical analyses and a two-sided *P* value of 0.05 or less was considered to be statistically significant. Heterogeneity among studies was evaluated by calculating the *I*^2^ statistic (significance level was set to I^2^ \> 50%) and chi-squared value (significance level set to *P* \< 0.10). I^2^ values of 25 and 75% were used as the criteria for classifying the degree of inter-trial heterogeneity (I^2^ \< 25%: low heterogeneity; I^2^ \> 25% and \< 75%: moderate heterogeneity: I^2^ \> 75%: high heterogeneity). If severe heterogeneity was present at I^2^ \> 50%, then a random-effects model was selected, otherwise the fixed-effects model was used. For results with a heterogeneity of \< 50% and a fixed-effects model, the stability would be explored by transformation into a random-effects model. Meta regression and subgroup analyses (≥ 6 studies) were conducted according to publication year, study design, country of origin, sepsis type, and the diagnostic criteria used for acute kidney injury and sepsis, on the condition of high inter-trial heterogeneity (I^2^ \> 50% and P \< 0.10). Sensitivity analysis of the overall risk (≥ 3 studies) was conducted by omitting 1 study each time in order to estimate the impact of individual studies. Publication bias was examined visually by the use of funnel plots, and the Egger's test was used to carry out asymmetric tests on the pooled data of ≥7 studies.

Results {#Sec8}
=======

Literature search (Fig. [1](#Fig1){ref-type="fig"}) {#Sec9}
---------------------------------------------------

In total, 8033 records were initially identified from the Medline, Embase, Cochrane Library, PubMed, and Web of Science, databases. By filtering the title and abstract, we were able to exclude duplicate articles, review studies, and studies on unrelated topics. In total, the full text of 626 studies was reviewed. After excluding comment papers, studies with inconsistent control settings, articles with unspecified AKI or sepsis diagnostic criteria, studies performed in special populations, and those with limited data, 47 articles met the inclusion criteria and were included in the systematic review and meta-analysis. Fig. 1Flow diagram showing search strategy and study selection. The diagram shows the numbers of titles and studies reviewed in preparation of this meta-analysis of development of acute kidney injury in sepsis patients. n represents the number of studies included in data syntheses. Eight included 'other' article represent that the study subjects included at least two of three sepsis (sepsis, septic shock and severe sepsis)

Characteristics of the included studies (Table [1](#Tab1){ref-type="table"}) {#Sec10}
----------------------------------------------------------------------------

The characteristics of the included articles are shown in Table [1](#Tab1){ref-type="table"}. Studies were published between 2008 and 2019 and originated from 18 countries (Spain, Greece, United Kingdom, France, Netherlands, Sweden, Canada, United States, Brazil, China, Japan, Saudi Arabia, Turkey, Finland, Portugal, South Korea and Australia) on four continents (Europe, America, Asia and Oceania). Overall, we included 12 retrospective cohort studies, 25 prospective cohort studies, and 12 case-control studies, with a total of 55,911 patients with sepsis. Document quality assessment showed that the methodological quality of all of the included studies was high, achieving a quality score of 8 (≥ 6). Table 1Characteristics of included studies in systematic review and meta-analysisAuthorPlublication yearCountryAKI diagnostic criteriaSepsis typesStudy periodResearch designNumble AKI VS No AKIQuality scoreBu et al. \[[@CR12]\]2019ChinaKDIGOSepsis and Septic shock2015--2017Retrospective case-control study132/907Hsu et al. \[[@CR13]\]2019ChinaAKINSepsis2012--2016Retrospective case-control study99/5976Vilander et al. \[[@CR14]\]2019FinlandKDIGOSepsis2011--2012Prospective cohort study300/3537Xing et al. \[[@CR15]\]2019ChinaKDIGOSeptic shock2018.8--2018.11Prospective cohort study29/438Moman et al. \[[@CR16]\]2018USAKDIGOSeptic shock2007--2009Retrospective cohort study160/738Zhi et al. \[[@CR17]\]2018ChinaAKINSepsis2009--2015Retrospective case-control study315/2675Zhou et al. \[[@CR18]\]2018ChinaAKINSepsis2010--2017Retrospective case-control study405/3486Costa et al. \[[@CR19]\]2018BrazilKDIGOSeptic shock2014--2015Prospective cohort study66/637Song et al. \[[@CR20]\]2018ChinaKDIGOSepsis2015--2016Prospective cohort study52/727Hu et al. \[[@CR21]\]2018ChinaRIFLESepsis2016--2017Prospective cohort study52/538Fatani et al. \[[@CR22]\]2018Saudi ArabiaRIFLESevere sepsis and Septic shock2016--2017Prospective cohort study127/737Gameiro et al. \[[@CR23]\]2017PortugalKDIGOSepsis and Septic shock2008--2014Retrospective case-control study399/576Katayama et al. \[[@CR24]\]2017JapanKDIGOSepsis2011--2016Retrospective case-control study163/3517Vilander et al. \[[@CR25]\]2017FinlandKDIGOSeptic shock2011--2012Prospective cohort study252/2267Suberviola et al. \[[@CR26]\]2017spainKDIGOSeptic shock2005--2010Prospective cohort study312/747Fisher et al. \[[@CR27]\]2017SwedenKDIGOSeptic shock--Prospective cohort study225/716Pérez-Fernández et al. \[[@CR28]\]2017USAKDIGOSevere sepsis and Septic shock2005--2007Prospective cohort study82/1787Pereira et al. \[[@CR29]\]2017PortugalREFILESevere sepsis and Septic shock2008--2014Retrospective case-control study384/727Panich et al. \[[@CR30]\]2017ThailandAKINSepsis2014--2014Prospective cohort study79/607Su et al. \[[@CR31]\]2016ChinaKDIGOSevere sepsis--Prospective cohort study45/276Yilmaz et al. \[[@CR32]\]2015TurkeyAKINSevere sepsis2011--2013Retrospective cohort study68/507Medeiros et al. \[[@CR33]\]2015JapaneseAKINSepsis2013--2014Retrospective cohort study144/568Dai et al. \[[@CR34]\]2015ChinaKDIGOSepsis2012--2014Prospective cohort study55/577Sood et al. \[[@CR35]\]2014CanadaRIFLESeptic shock1996--2008Prospective cohort study3298/11957Peng et al. \[[@CR36]\]2014ChinaKDIGOSepsis2008--2011Prospective cohort study101/1108Patschan et al. \[[@CR37]\]2014GermanyAKINSepsis--Retrospective case-control study22/117Tu et al. \[[@CR38]\]2014ChinaAKINSepsis2011--2013Prospective cohort study49/1016Fan et al. \[[@CR39]\]2014ChinaRIFLESepsis2012--2014Prospective cohort study58/677CHO et al. \[[@CR40]\]2014KoreaRIFLESepsis2010--2011Prospective cohort study44/187Terzi et al. \[[@CR41]\]2014GreeceRIFLESepsis--Prospective cohort study16/296Poukkanen et al. \[[@CR42]\]2013FinlandKDIGOSevere sepsis2011--2012Retrospective case-control study153/2707Legrand et al. \[[@CR43]\]2013FranceAKINSevere sepsis and Septic shock2006--2010Prospective cohort study69/688Cardinal-Fernández et al. \[[@CR44]\]2013SpainRIFLESevere sepsis2005--2008Prospective cohort study65/747de Geus et al. \[[@CR45]\]2013NetherlandsAKINSepsis2007--2008Prospective cohort study49/4327Katagiri et al. \[[@CR46]\]2013JapanRIFLESepsis2010--2011Prospective cohort study24/106Aydogdu et al. \[[@CR47]\]2013TurkeyRIFLESepsis2008--2010Prospective cohort study63/667Suh et al. \[[@CR48]\]2013South KoreanRIFLESepsis and Septic shock2010Retrospective case-control study573/4198Poukkanen et al. \[[@CR49]\]2013FinlandKDIGOSevere sepsis2011--2012Retrospective case-control study437/3937Zhao et al. \[[@CR50]\]2013ChinaAKINSepsis2011--2013Retrospective case-control study90/586Payen et al. \[[@CR51]\]2012BrazilAKINSevere sepsis and Septic shock2004--2005Retrospective cohort study129/476Frank et al. \[[@CR52]\]2012USAAKINSeptic shock1999--2009Retrospective cohort study627/6377Plataki et al. \[[@CR53]\]2011USARIFLESeptic shock2005--2007Retrospective cohort study237/1537Ma°rtensson et al. \[[@CR54]\]2010SwedenRIFLE OR AKINSeptic shockProspective cohort study18/76YANG et al. \[[@CR55]\]2009ChinaAKINSeptic shock2001--2008Retrospective cohort study126/327Lopes et al. \[[@CR56]\]2009PortugalAKINSepsis2004--2007Retrospective cohort study99/2167Bagshaw et al. \[[@CR57]\]2009Canada, the United States and SaudiArabiaRIFLESeptic shock1989--2005Retrospective cohort study2917/16157Bagshaw et al. \[[@CR58]\]2008AustraliaRIFLESepsis2000--2005Retrospective cohort study14,039/193368

Summary data from the included studies (Table [2](#Tab2){ref-type="table"}) {#Sec11}
---------------------------------------------------------------------------

This study summarized the characteristics of sepsis patients who developed AKI. ICU mortality, hospital mortality, 28-day mortality, and 90-day mortality, of patients with S-AKI were respectively reported at 45.99% (1989/4325 cases) in 15 studies, 49.84% (2732/5481) in 10 studies, 36.67% (161/439) in 4 studies, and 64.66% (2406/3721) in 5 studies., respectively. In S-AKI patients, the highest mortality rate for AKI was caused by septic shock; severe sepsis was associated with the lowest mortality rate. Table 2Summary data of all sepsis patients who developed AKI from included studiesCharacteristicNo.StudiesPrevalenceSepsisSeptic shockSevere sepsisNo.StudiesPrevalenceNo.StudiesPrevalenceNo.StudiesPrevalenceSeptic AKI4748.73% (27,248/55911)2241.98% (16,399/39067)1260.47%(12,678/20965)538.92% (768/1570)Sex (male)4459.70% (5913/9904)2263.68% (1380/2167)1159.64% (3191/5350)564.45% (495/768)Comorbidities Hypertension3238.39% (3263/8500)1442.28% (859/1817)626.16% (1073/4102)558.07% (446/768) Diabetes mellitus3227.57% (2248/8155)1320.53% (373/1817)726.75% (1897/7091)530.20% (232/768) Stroke422.79% (67/294)122.33% (67/300)----117.78% (8/45) Cancer618.23% (705/3745)----218.80% (650/3458)116.33% (8/49) Chronic kidney disease1416.46% (449/2795)715.52% (178/1147)245.13% (102/226)211.02% (65/590) Cardiovascula disease1116.30% (2522/15477)419.47% (169/868)----17.00% (3/45) Congestive heart failure712.69% (491/3869)217.26% (39/226)412.64% (446/3529)18.80% (6/68) COPD1712.41% (1114/8976)612.69% (90/709)512.99% (873/6721)15.20% (25/437) Hepatic failure412.16% (449/3691)239.76% (134/337)19.90% (290/2917)312.61% (83/658) Coronary artery disease811.58% (457/3948)410.14% (88/868)29.30% (274/2946)16.15% (4/65) Systolic heart failure411.25% (135/1200)18.00% (24/300)214.32% (59/412)111.90% (52/437) Immnosuppression710.35% (1888/18249)212.74% (1300/14204)315.80% (550/3481)17.20% (35/437) Cirrhosis64.71% (99/2104)11.73% (7/405)27.50% (59/787)---- Liver disease73.74% (554/14081)33.57% (509/14282)18.73% (22/252)28.59% (17/198)Admission category Emergency admission750.88% (9235/18149)250.90% (7298/14339)241.46% (1314/3169)297.12% (573/590) Medical admission847.02% (8701/18506)349.16% (6938/14112)236.99% (1311/3544)---- Operative admission530.91% (353/1142)122.33% (67/300)123.02% (58/252)228.81% (170/590) Surgical ward717.73% (3787/21359)316.51% (2375/14388)321.29% (1380/6482)----Source of infection Pulmonary1946.05% (1480/3214)857.96% (448/773)541.10% (603/1467)348.02% (316/658) Respiratory732.08% (273/85)241.22% (54/131)232.74% (74/226)226.36% (29/110) Abdominal2530.87% (2152/6971)732.12% (177/551)728.16% (1253/4450)528.65% (220/768) Urinary tract1911.14% (630/5653)612.01% (58/483)611.34% (483/4259)511.38% (80/703) Skin or soft tissue136.03% (335/5554)32.15% (5/232)45.40% (218/4033)310.71% (68/635) Unknow46.02% (100/1662)----28.30% (73/879)---- Community acquired357.36% (2041/3558)----156.80% (1657/2917)265.08% (384/590) Nosocomial acquired239.81% (2474/6215)----239.81% (2474/6215)----Medications Vasopressors764.61% (1293/2001)345.04% (100/222)259.38% (513/864)---- vasoactive drugs563.22% (911/1441)235.69% (131/367)167.50% (108/160)296.44% (569/590) Steroids330.80% (85/276)238.16% (79/207)-------- Diuretics430.77% (296/962)----139.40% (97/252)230.85% (182/590) ACEI or ARB825.62% (619/2416)118.41% (58/315)324.97% (200/801)333.59% (220/655) Stains521.77% (357/1640)----224.13% (118/489)115.79% (69/437) Nsaids9.63% (203/2108)116.19% (51/315)211.45% (56/489)212.54% (74/590)Bacteria Gram-negative bacteria317.26% (160/927)----122.3% (49/225)---- Gram-positive bacteria410.43% (99/949)118.20% (4/22)128.6% (63/225)----Invasive treatment Mechanical ventilation2368.00% (7167/10539)749.17% (415/844)671.21% (5481/7643)475.25% (529/703) renal replacement therapy639.51% (320/810)136.53% (19/52)118.18% (12/66)---- Dialysis328.92% (59/204)235.04% (48/137)-------- Blood transfusion319.46% (94/483)17.64% (11/144)227.39% (3/303)---- Organ transplant33.76% (252/6703)----23.94% (245/6215)11.60% (7/437)Positive blood culture841.38% (3259/7876)----442.89% (2836/6612)230.29% (146/482)Bloodstream infection46.61% (237/3586)117.31% (9/52)17.40% (216/2917)14.70% (6/437)Smoke history543.09% (642/1490)240.42% (291/720)----132.35% (22/68)ARDS347.02% (489/1040)181.19% (82/101)243.34% (407/939)----Multiorgan dysfunction (≥3)350.11% (436/870)170.48% (222/315)--------Mortality ICU mortality1045.99% (1989/4325)250.00% (46/92)450.47% (1672/3313)135.38% (23/65) Hospital mortality1549.84% (2732/5481)742.17% (245/581)355.83% (1935/3466)129.29% (128/437) 28-day mortality436.67% (161/439)130.61% (15/49)171.42% (90/126)---- 90-day morality564.66% (2406/3721)----158.42% (1704/2917)240.0% (236/590)*COPD* chronic obstructive pulmonary disease, *ACEI or ARB* angiotensin converting enzyme inhibitors or Angiotensin Receptor Blocker, *ARDS* acute respiratory distress syndrome

The most prevalent comorbidity was ARDS (47.02%; 489/1040; from 3 studies), followed by hypertension (38.39%; 3263/8500; from 32 studies), diabetes (27.57%; 2248/8155; from 32 studies) and stroke (22.79%; 67/294;from 4 studies), while cirrhosis and liver disease accounted for only 4.71% (99/2104; from 6 studies) and 3.74% (554/14081; from 7 studies), respectively. Hepatic failure was more common in patients with sepsis compared with those with septic shock and severe sepsis. Hypertension in patients with septic shock was less common than sepsis and severe sepsis (26.16% vs 42.28 and 58.07%), while chronic kidney disease was more prevalent (45.13% vs 15.52 and 11.02%). Hypertension and diabetes were more prevalent in patients with severe sepsis than in sepsis and septic shock (58.7% vs 42.28 and 26.16%, 30.20% vs 20.53 and 26.75%).

On admission, patient source mainly included emergency admission (50.88%; 9235/18149; from 8 studies) and medical admission (47.02%; 8701/18506; from 7 studies), followed by operative admission and surgical ward. Vasoactive drugs were the most commonly used drugs, accounting for 64.61% of cases (1293/2001; from 5 studies), of which vasopressors were the most frequently used, accounting for 63.22% of cases (911/1441; from 7 studies), followed by steroids, diuretics, ACEI or ARB, stains, and NSAIDS. Vasoactive drugs and vasopressors were more prevalent in patients with septic shock and severe sepsis than in patients with sepsis.

Six sources of infection were reported in this study, including pulmonary infection (46.05%; 1480/3214; from 19 studies), respiratory infection (32.08%; 85/273; from 7 studies), abdominal infection (30.87%; 2152/6971; from 25 studies), urinary tract infection (11.14%; 630/5653; from 19 studies), skin or soft tissue infection (6.03%; 335/5554; from 13 studies), and unknown infections (6.02%; 100/1662; from 4 studies).

Community acquired infection was reported in 3 studies with a prevalence of 57.36% (2041/3558), which was higher than nosocomial acquired infection, reported in 2 studies (39.81%; 2474/6215). Twenty-four studies reported mechanical ventilation in 68.00% of patients (7167/10539; from 24 studies), and mechanical ventilation was more frequently used in patients with septic shock and severe sepsis compared with patients with sepsis. Other prevalent factors included positive blood culture (41.38%; 3259/7876; from 8 studies) and smoking history (43.09%; 642/1490; from 5 studies).

Risk factors for AKI (Fig. [2](#Fig2){ref-type="fig"}) {#Sec12}
------------------------------------------------------

### Comorbidities {#Sec13}

Pooled data from 32 studies indicated that hypertension was a significant predictor (OR: 1.43; 95% CI: 1.20--1.70) with moderate heterogeneity (I^2^ = 74.00%). The source of heterogeneity was not identified by subgroup analysis. The results of the sensitivity analyses were consistent. After excluding 3 studies with rather high heterogeneity, the level of heterogeneity decreased, and the result remained stable (see Additional file [2](#MOESM2){ref-type="media"}). Fig. 2Meta-analysis of risk factors of AKI

Pooled data from 32 studies indicated that diabetes mellitus was a significant predictor (OR: 1.59; 95% CI: 1.47--1.71) with moderate heterogeneity (I^2^ = 37.1%). The results remained stable even with a random-effects model (see Additional file [3](#MOESM3){ref-type="media"}).

Pooled data from 14 studies indicated that chronic kidney disease was a significant predictor (OR: 3.49; 95% CI: 2.36--5.15) with moderate heterogeneity (I^2^ = 71.70%). The source of heterogeneity was not identified by subgroup analysis. The results of sensitivity analyses were consistent. After excluding one study with high heterogeneity, I^2^ was reduced to 25.6% (low heterogeneity) and the result remained stable (see Additional file [4](#MOESM4){ref-type="media"}).

Cardiovascular disease (from 14 studies; OR: 1.31; 95% CI: 1.24--1.40) and liver disease (from 17 studies; OR: 1.68; 95% CI: 1.47--1.90) were identified as risk factors with low levels of heterogeneity. The results remained stable even with a random-effects model (see Additional files [5](#MOESM5){ref-type="media"} and [6](#MOESM6){ref-type="media"}).

Pooled data from 8 studies indicated that coronary artery disease was a significant predictor (OR: 1.27; 95% CI: 1.08--1.49) with moderate heterogeneity (I^2^ = 37.1%). The results remained stable with the random-effects model (see Additional file [7](#MOESM7){ref-type="media"}).

### Source of infection {#Sec14}

Pooled data from 8 studies indicated that pulmonary infection was a significant predictor (OR: 0.77; 95% CI: 0.60--0.99) with moderate heterogeneity (I^2^ = 77.60%). The source of heterogeneity was not identified by subgroup analysis. The results of sensitivity analyses were consistent (see Additional file [8](#MOESM8){ref-type="media"}).

Pooled data from 25 studies indicated that abdominal infection was a significant predictor (OR: 1.44; 95% CI: 1.32--1.58) with moderate heterogeneity (I^2^ = 40.20%). The results of the sensitivity analyses were consistent. After excluding one study with high levels of heterogeneity, the results remained stable; the results were also stable with the fixed-effects model (see Additional file [9](#MOESM9){ref-type="media"}).

Pooled data from 25 studies indicated that unknown infection was a significant predictor (OR: 2.01; 95% CI: 1.35--2.98) with low heterogeneity (I^2^ = 0%). The results were still stable with the random-effects model (see Additional file [10](#MOESM10){ref-type="media"}).

### Medications {#Sec15}

Vasopressors (from 7 studies; OR: 3.15; 95% CI: 2.00--4.96) and ACEI or ARB (from 8 studies; OR: 1.61; 95% CI: 1.10--2.36) were all identified as risk factors with high levels of heterogeneity (I^2^ ≥ 75%). The source of heterogeneity was not identified by subgroup analysis and the sensitivity analyses were stable (see Additional file [11](#MOESM11){ref-type="media"}).

Pooled data from 5 studies indicated that diuretics were a significant predictor (OR: 1.40; 95% CI: 1.13--1.72) with low levels of heterogeneity (I^2^ = 0%). The results remained stable with the random-effects model (see Additional file [12](#MOESM12){ref-type="media"}) (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Forest plot for meta-analysis of the association of male sex and AKI

### Other factors {#Sec16}

Pooled data from 43 studies indicated that male gender was a significant predictor (OR: 1.22; 95% CI: 1.06--1.40) with moderate heterogeneity (I^2^ = 69.80%). The source of heterogeneity was not identified by subgroup analysis. The results arising from sensitivity analyses were consistent (see Additional file [13](#MOESM13){ref-type="media"}).

Pooled data from 9 studies indicated that positive blood culture was a significant predictor (OR: 1.60; 95% CI: 1.35--1.89) with moderate heterogeneity (I^2^ = 50.20%). The source of heterogeneity was not identified by subgroup analysis. The sensitivity analysis results were consistent (see Additional file [14](#MOESM14){ref-type="media"}).

Pooled data from 5 studies indicated that smoking history was a significant predictor (OR: 1.60; 95% CI: 1.09--2.36) with high heterogeneity (I^2^ = 78.30%). Results arising from sensitivity analysis were consistent. After excluding one study with high levels of heterogeneity, the result remained stable (see Additional file [15](#MOESM15){ref-type="media"}).

Pooled data from 7 studies indicated that septic shock was a significant predictor (OR: 1.40; 95% CI: 1.13--1.72) with low heterogeneity (I^2^ = 8.2%). The results were still stable with the random-effects model (see Additional file [16](#MOESM16){ref-type="media"}).

Gram-negative bacteria (from 3 studies; OR: 2.19; 95% CI: 1.52--3.15) and organ transplantation (from 3 studies; OR: 1.96; 95% CI: 1.48--2.61) were all identified as risk factors with low levels of heterogeneity (I^2^ = 0%); the results remained stable with the random-effects model (see Additional files [17](#MOESM17){ref-type="media"} and [18](#MOESM18){ref-type="media"}).

Pooled data from 24 studies indicated that mechanical ventilation was a significant predictor (OR: 1.64; 95% CI: 1.24--2.16) with high levels of heterogeneity (I^2^ = 88.70%). The source of heterogeneity was not identified by subgroup analysis. The sensitivity analysis results were consistent (see Additional file [19](#MOESM19){ref-type="media"}) (Fig. [4](#Fig4){ref-type="fig"}). Fig. 4Funnel plot to detect publication bias for male sex, Egger test, *P* = 0.32

Tests for publication Bias (Fig. [2](#Fig2){ref-type="fig"}) {#Sec17}
------------------------------------------------------------

Egger's rank correlation test and Egger's linear regression test indicated that there was no publication bias for any of the risk factors (≥7 studies) except for cardiovascular disease (*P* = 0.015). Due to the limited number of studies (\<7 studies), publication bias was not evaluated for smoking history, cirrhosis, multiorgan dysfunction (≥3), unknown infection, the administration of vasoactive drugs, the use of diuretics, and organ transplantation (Fig. [5](#Fig5){ref-type="fig"}). Fig. 5Subgroup analyzes for meta-analysis of the association of pulmonary infection and AKI

Discussion {#Sec18}
==========

Major findings {#Sec19}
--------------

To the best of our knowledge, this is the first meta-analysis to provide a comprehensive insight into the risk factors associated with AKI in patients with sepsis. In total, 47 studies, including 55,911 patients with sepsis, were included in this systematic review, along with 46 risk factors. The results showed that 19 factors were significant, including comorbidities, sources of infection, medications, and invasive treatments. Risk factors for S-AKI arise from a wide range of sources, making it difficult to predict and prevent this disease. We found that AKI caused by septic shock had the highest incidence and mortality in patients with sepsis. We also found significant inter-trial heterogeneity in studies exploring the association between sepsis and AKI, thus resulting in reduced evidential power. Inevitably, this has led to controversial opinions regarding the risk factors for AKI in patients with sepsis. We, therefore, hope that more homogeneous research can be carried out in the future and more reliable conclusions can be obtained.

Analysis of risk factors {#Sec20}
------------------------

Risk factors for sepsis-associated AKI can be categorized as pre-sepsis risk factors, sepsis disease-related factors and sepsis-related treatment factors. The pre-sepsis risk factors (e.g., concurrent chronic diseases, gender, age, and smoking history) and sepsis disease itself (e.g., sepsis type, source of infection, and bacterial infection) cannot be altered since they existed at the time of diagnosis. However, these factors can be used to identify patients who are at high risk of AKI, so that timely precautions can be applied accordingly to reduce potential risks in the future. On the other hand, the risk factors associated with sepsis-related treatment can be manually controlled by using efficient strategies (e.g., medication and mechanical ventilation).

### Pre-sepsis risk factors {#Sec21}

Our study showed that multiple chronic comorbidities were associated with the development of AKI in patients with sepsis. Hypertension and diabetes mellitus were the most common risk factors for AKI among all comorbidities; other factors included chronic kidney diseases, cardiovascular diseases, coronary artery diseases, and liver diseases. This may be due to the fact that the majority of patients with sepsis were older adults aged 65 years and older \[[@CR6], [@CR59]\]. We found that diabetes mellitus and hypertension were associated with higher risks of AKI; these findings were consistent with those of previous studies \[[@CR60]--[@CR63]\]. Chronic kidney disease has been recognized as a significant risk factor for AKI \[[@CR64], [@CR65]\]. Moreover, when AKI occurs in CKD patients, it is more severe and difficult to recover from. There is increasing recognition that AKI and chronic kidney disease (CKD) are closely linked and are likely to promote one another. However, the association between the severity of CKD (e.g., as measured by levels of estimated GFR) and the risk of AKI has not been quantified, although a recent meta-analysis showed that CKD may increase the risk of AKI in patients with diabetes or hypertension. Therefore, in addition to directly increasing the risk of AKI, diabetes mellitus, hypertension, and CKD, could also interact to promote the development of AKI \[[@CR63]\]. Furthermore, these three factors are also prevalent risk factors for AKI. Consequently, more attention should be paid to patients with these three risk factors in order to avoid the potential risks of AKI.

Opinions regarding the association between gender and AKI remain controversial, although our study found that male patients may be at a slightly higher risk of AKI compared with their female counterparts. A previous study found that a lower glomerular filtration rate (eGFR) and a higher albumin-creatinine ratio (ACR) were associated with higher AKI risks in both men and women, and that male gender was associated with a higher risk of AKI with a slight attenuation in a lower eGFR but not with a higher ACR \[[@CR66]\].

### Sepsis-disease-related risk factors {#Sec22}

Among the patients with sepsis that were included in the present study, we found that AKI caused by septic shock had the highest incidence and mortality, and that septic shock was also a significant risk factor for AKI. Consequently, more attention should be paid to the prevention of AKI in patients with septic shock.

Our data analysis indicated that pulmonary and abdominal infections were the most common source of infection in patients with sepsis who developed AKI. We also found that both of these conditions were associated with the development of AKI. Abdominal infections could increase the risk of AKI development, although our study found that lung infection was a protective factor for AKI, although further research is needed to elucidate the mechanisms underlying this observation. Considering the high levels of heterogeneity (I^2^ = 77.6%), we performed sensitivity analyses an obtained stable results. Subgroup analysis showed different results when considering Chinese populations and other populations. Pulmonary infection was found to be a risk factor in the Chinese population (OR: 1.62; 95% CI: 1.06--2.49) but was a protective factor in other populations (OR: 0.61; 95% CI: 0.50--0.74). We were cautious about the overall results and the results of our subgroup analysis since there was a lack of reasonable interpretation for these results, as well as heterogeneity among different populations. Further research is required to investigate these issues further.

The specific relationship between the occurrence of AKI and bacterial infection has rarely been reported. Our study found that gram-negative bacteria may represent a risk factor for AKI. However, it remains unclear which gram-negative bacteria could be involved. Only one study showed that *Escherichia coli* may be associated with the development of AKI \[[@CR66]\]. Further research is now needed to investigate this relationship further.

### Sepsis-related treatment risk factors {#Sec23}

Our study found that diuretics, vasopressors, and ACEI or ARB, could be associated with the occurrence of AKI. Vasoactive drugs are commonly used in patients with sepsis, especially septic shock. Our research found that vasopressors increased the risk of AKI, while the association between AKI and other vasoactive medications remains uncertain. A large cohort study previously showed that ACEI/ARB could be associated with a small increase in the risk of AKI while individual patient characteristics were much more closely correlated with the incidence of AKI \[[@CR67]\]. Among patients with CKD, there was no increased risk of developing AKI compared with those who were not exposed to ACEI/ARB, while exposure to ACEI/ARB in patients without CKD increased the risk of AKI. An earlier multi-center prospective study in Shanghai showed that diuretics accounted for 22.2% of all drug-induced cases of AKI, ranked only after antibiotics \[[@CR68]\]. The reasons for the association between the use of diuretics and an increased risk of AKI could be interpreted as follows. First, loop diuretics block sodium chloride uptake in the macula densa in a manner that is independent of any effect on sodium and water balance, thereby stimulating the renin-angiotensin-aldosterone system (RAAS) and leading to AKI. Sometimes, AKI is caused by the combined action of diuretics and other drugs, which may include antibiotics, contrast media, ACEI/ARB, and NSAIDs \[[@CR69]\]. Another study showed that a triple therapy combination consisting of diuretics with ACEI or ARB and NSAIDs was associated with an increased risk of AKI \[[@CR70]\]. However, the high levels of heterogeneity related to these factors cannot be ignored. Furthermore, our subgroup analyses failed to identify the specific sources of such heterogeneity. Therefore, these results should be interpreted with caution. Such heterogeneity may originate from the specific types, duration, and dosage of drugs and their interactions with other drugs. More homogeneous clinical randomized trials should be conducted in patients with sepsis to confirm the specific role of these drugs and their interactions in inducing AKI.

Many studies have confirmed that mechanical ventilation is a risk factor for AKI; our present findings concur with these previous findings \[[@CR71], [@CR72]\]. A previous study showed that mechanical ventilation is used in up to 75% of patients in ICU \[[@CR73]\]. Our analyses showed that 68% of patients with sepsis who developed AKI also used mechanical ventilation; this proportion is even higher in patients with septic shock and severe sepsis. Therefore, we have to pay special attention to prevent the development of AKI in patients undergoing mechanical ventilation. Hypoxemia, hypercapnia, and excessive positive end-expiratory pressure (PEEP) values during mechanical ventilation are all risk factors for AKI. If there are other risk factors at the same time, AKI is more likely to occur. At present, there is no useful method to prevent or reduce the AKI caused by mechanical ventilation. Some studies have shown that the development of AKI can be reduced by adjusting ventilator parameters, improving hypoxia status as soon as possible, avoiding persistent hypercapnia, and by using smaller PEEP settings. However, a previous meta-analysis showed that invasive MV could be associated with a threefold increase in the odds of AKI in critically ill patients, and tidal volume (Vt) and PEEP settings do not modify this risk \[[@CR72]\]. Therefore, future research should focus on strategies that can reduce the risks of AKI induced by mechanical ventilation.

Limitations {#Sec24}
-----------

Our study has some limitations that should be considered. First, all of our results were based on unadjusted estimates due to the significant variability of multivariable models across different studies. Therefore, we may have failed to identify independent predictors for AKI in the presence of confounding factors. Secondly, significant heterogeneity was observed for certain risk factors due to varied geographic locations, demographic data, and inconsistent diagnostic criteria for AKI and sepsis. We did not identify the source of this heterogeneity in our subgroup analyses; this issue may have impacted on our results. In addition, due to the small number of studies, heterogeneity and publication bias were not evaluated for certain risk factors.

Conclusion {#Sec25}
==========

Our analyses showed that the most common risk factors for S-AKI were septic shock, hypertension, diabetes mellitus, abdominal infection, a history of smoking, positive blood cultures, the use of vasopressors, and mechanical ventilation. Other risk factors included cardiovascular and coronary artery disease, liver disease, unknown infections, the use of diuretics, the use of ACEI or ARB, gram-negative bacteria infections, and organ transplantation. Despite our rigorous methodology, the inherent limitations of the included studies prevented us from reaching definitive conclusions. However, this article is the first systematic review and meta-analysis to investigate the risk factors for AKI development in patients with sepsis. Our findings may facilitate the development of clinical targeted care strategies for the prevention, detection and management of AKI in patients with sepsis.
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AKI

:   Acute kidney injury

S-AKI

:   Sepsis-associated acute kidney injury

ARF

:   Acute renal failure

OR

:   Odds ratio

CI

:   Confidence interval

CKD

:   Chronic kidney disease

KDIGO

:   Kidney disease improving global outcomes

AKIN

:   Acute kidney injury network classification

RIFLE

:   Risk, injury, failure, end stage kidney disease

NSAIDs

:   Non-steroidal anti-inflammatory drugs

COPD

:   Chronic obstructive pulmonary disease

ACEI or ARB

:   Angiotensin converting enzyme inhibitors or Angiotensin receptor blocker

PEEP

:   Positive end-expiratory pressure

MV

:   Mechanical ventilation
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